Magforce USA Inc., of Nevada, completed a capital increase by exercising 700,000 subscription rights and issuing 166,666 new shares of the company. The subscription rights were issued in 2014 to U.S. investors as part of a growth financing round and had a term limit of four years. There are no outstanding subscription rights remaining after the exercise. The issuance of a total of 866,666 new shares will generate gross proceeds of approximately $9 million. The new Magforce USA Inc. shares were subscribed by a new U.S. investor. Proceeds from the capital increase will be used to finance the initiated pivotal clinical trial in the U.S. with Nanotherm Therapy for focal tumor ablation in intermediate risk prostate cancer and associated business operations.

Staar Surgical Co., a Monrovia, Calif.-based developer of implantable lenses and companion delivery systems for the eye, reported an underwritten public offering of 1.74 million shares of its common stock, for total gross proceeds of approximately $67.8 million. Staar has granted the underwriters of the offering a 30-day option to purchase up to an additional 260,850 shares of its common stock on the same terms and conditions. The closing of the offering is expected to occur Aug. 10, 2018. Canaccord Genuity is acting as the sole book-running manager for the offering.

Tandem Diabetes Care Inc., of San Diego, closed an underwritten public offering of 3.5 million shares of common stock at a price of $28.50 per share. In addition, the underwriters fully exercised an option to purchase 526,315 additional shares of common stock at the public offering price. All of the shares in the offering were offered by Tandem, with gross proceeds to Tandem of approximately $115 million. Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering. Robert W. Baird & Co. Inc. acted as a co-manager. Tandem manufactures and sells the T:slim X2 insulin pump with Basal-IQ technology.

Volitionrx Ltd., Singapore-based developer of blood tests to help diagnose a range of cancers, entered a definitive agreement with an existing accredited investor related to a private placement offering of 5 million shares of Volition common stock at a price of $1.80 per share, as well as a warrant to purchase up to an additional 5 million shares of Volition common stock at an exercise price of $3.00 per share payable in cash, which will result in gross proceeds to Volition of $9 million (excluding the proceeds from any exercise of the warrant). The warrant will have a term of one year from the closing date and be exercisable for a period of six months. The private placement is expected to close Aug. 10, 2018. Volition intends to use the net proceeds of the private placement for continued product development, clinical studies, product commercialization and general corporate purposes.

No Comments